DDInter48 DDInter364
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout. It was initially approved by the FDA in 1966 and is now formulated by several manufacturers.
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Allopurinol {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Allopurinol {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Allopurinol {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Allopurinol {u} (Compound) treats {v} (Disease) gout
gout {u} (Disease) is treated by {v} (Compound) Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Allopurinol {u} (Compound) binds {v} (Gene) SLC22A8
SLC22A8 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Allopurinol (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Chlorpropamide (Compound)
Allopurinol (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Allopurinol (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Allopurinol (Compound) treats gout (Disease) and gout (Disease) is treated by Probenecid (Compound) and Probenecid (Compound) resembles Chlorpropamide (Compound)
Allopurinol (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Probenecid (Compound) and Probenecid (Compound) resembles Chlorpropamide (Compound)